SCHEMBL386474

SCHEMBL386474

[CH2]CC(CCCCC)NC

nearest known ligand 0.39

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.39
OPRM1 P35372 1/20 0.37
LMNA P02545 1/20 0.34
DNM1 Q05193 2/20 0.33
ADH1B P00325 1/20 0.33
ADH1C P00326 1/20 0.33
ADH1A P07327 1/20 0.33
ADH4 P08319 1/20 0.33
ADH7 P40394 1/20 0.33
FDPS P14324 3/20 0.32
TSHR P16473 1/20 0.32
THRB P10828 1/20 0.32
ZDHHC7 Q9NXF8 1/20 0.31
GPR84 Q9NQS5 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL387419 0.98 EPHX1 (0.42) EPHX1OPRM1LMNADNM1ADH1B
SCHEMBL385700 0.93
SCHEMBL22344696 0.82 EPHX1 (0.50) EPHX1OPRM1LMNADNM1ADH1B
SCHEMBL22344697 0.82 EPHX1 (0.50) EPHX1OPRM1LMNADNM1ADH1B
SCHEMBL22344693 0.82 EPHX1 (0.50) EPHX1OPRM1LMNADNM1ADH1B
SCHEMBL25137858 0.82 EPHX1 (0.50) EPHX1OPRM1LMNADNM1ADH1B
SCHEMBL23851606 0.82 EPHX1 (0.50) EPHX1OPRM1LMNADNM1ADH1B
SCHEMBL25137857 0.82 EPHX1 (0.50) EPHX1OPRM1LMNADNM1ADH1B
SCHEMBL22344694 0.82 EPHX1 (0.50) EPHX1OPRM1LMNADNM1ADH1B
SCHEMBL24702390 0.82 EPHX1 (0.50) EPHX1OPRM1LMNADNM1ADH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101650-B2 Method for treating a immunology-related disease DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-01-24 US disclosed
US-8067396-B2 Amino alcohol compounds or phosphonic acid derivatives thereof SANKYO COMPANY, LIMITED (JP) 2011-11-29 US disclosed
US-7910617-B2 Method for suppressing the number of peripheral blood lymphocytes using an amino alcohol compound SANKYO COMPANY, LIMITED (JP) 2011-03-22 US disclosed
CN-1921847-B Amino alcohol compound SANKYO CO 2010-06-16 CN disclosed
US-20100035842-A1 Amino alcohol compounds or phosphonic acid derivatives thereof SANKYO COMPANY, LIMITED (JP) 2010-02-11 US disclosed
US-20090326038-A1 Method for treating a immunology-related disease SANKYO COMPANY, LIMITED (JP) 2009-12-31 US disclosed
US-7638551-B2 Amino alcohol compounds or phosphonic acid derivatives thereof SANKYO COMPANY, LIMITED (JP) 2009-12-29 US disclosed
EP-1471054-B1 AMINO ALCOHOL DERIVATIVE OR PHOSPHONIC ACID DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THESE DAIICHI SANKYO CO LTD (JP) 2009-07-01 EP disclosed
CN-100415735-C Amino alcohol derivatives SANKYO CO (JP) 2008-09-03 CN disclosed
CN-100406437-C Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing them SANKYO CO (JP) 2008-07-30 CN disclosed
US-6964976-B2 Amino alcohol derivatives SANKYO COMPANY, LIMITED (JP) 2005-11-15 US disclosed
CN-1680563-A Amino alcohol derivatives SANKYO CO (JP) 2005-10-12 CN disclosed
CN-1630635-A Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these SANKYO CO (JP) 2005-06-22 CN disclosed
US-20050043386-A1 Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these SANKYO COMPANY, LIMITED (JP) 2005-02-24 US disclosed
EP-1471054-A1 AMINO ALCOHOL DERIVATIVE OR PHOSPHONIC ACID DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THESE Sankyo Company, Limited (JP) 2004-10-27 EP disclosed
US-20040132784-A1 Amino alcohol derivatives SANKYO COMPANY, LIMITED (JP) 2004-07-08 US disclosed
CN-1494540-A Amino alcohol derivatives ������������ʽ���� 2004-05-05 CN disclosed
US-6723745-B2 PREVENTION OR TREATMENT OF AUTOIMMUNE DISEASE IN WARM BLOODED ANIMAL SANKYO COMPANY, LIMITED (JP) 2004-04-20 US disclosed
US-20030236297-A1 Amino alcohol derivatives SANKYO COMPANY, LIMITED (JP) 2003-12-25 US disclosed
EP-1300405-A1 AMINO ALCOHOL DERIVATIVES Sankyo Company, Limited (JP) 2003-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236297-A1 Amino alcohol derivatives CD4, ADH1C, ADH1A EPHX1 3205/4885OPRM1 163/4885LMNA 3703/4885
US-20050043386-A1 Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these PHOSPHO1, CD4, FCGRT EPHX1 2839/4885OPRM1 575/4885LMNA 4143/4885
US-20040132784-A1 Amino alcohol derivatives CD4, ADH1C, ADH1A EPHX1 3205/4885OPRM1 163/4885LMNA 3703/4885
US-20090326038-A1 Method for treating a immunology-related disease C3AR1, HRH3, HRH2 EPHX1 941/4885OPRM1 3794/4885LMNA 3060/4885
US-20100035842-A1 Amino alcohol compounds or phosphonic acid derivatives thereof PHOSPHO1, ADH1C, ADH1A EPHX1 2229/4885OPRM1 753/4885LMNA 1759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.